Literature DB >> 6196195

A poliovirus type 1 neutralization epitope is located within amino acid residues 93 to 104 of viral capsid polypeptide VP1.

C Wychowski, S van der Werf, O Siffert, R Crainic, P Bruneau, M Girard.   

Abstract

Using nuclease Bal31, deletions were generated within the poliovirus type 1 cDNA sequences, coding for capsid polypeptide VP1, within plasmid pCW119. The fusion proteins expressed in Escherichia coli by the deleted plasmids reacted with rabbit immune sera directed against poliovirus capsid polypeptide VP1 (alpha VP1 antibodies). They also reacted with a poliovirus type 1 neutralizing monoclonal antibody C3, but reactivity was lost when the deletion extended up to VP1 amino acids 90-104. Computer analysis of the protein revealed a high local density of hydrophilic amino acid residues in the region of VP1 amino acids 93-103. A peptide representing the sequence of this region was chemically synthesized. Once coupled to keyhole limpet hemocyanin, this peptide was specifically immunoprecipitated by C3 antibodies. The peptide also inhibited the neutralization of poliovirus type 1 by C3 antibodies. We thus conclude that the neutralization epitope recognized by C3 is located within the region of amino acids 93-104 of capsid polypeptide VP1.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6196195      PMCID: PMC555403          DOI: 10.1002/j.1460-2075.1983.tb01694.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  33 in total

1.  Tapping the immunological repertoire to produce antibodies of predetermined specificity.

Authors:  R A Lerner
Journal:  Nature       Date:  1982-10-14       Impact factor: 49.962

2.  Immunogenic structure of the influenza virus hemagglutinin.

Authors:  N Green; H Alexander; A Olson; S Alexander; T M Shinnick; J G Sutcliffe; R A Lerner
Journal:  Cell       Date:  1982-03       Impact factor: 41.582

3.  A neutralizing monoclonal antibody against poliovirus and its reaction with related antigens.

Authors:  J Icenogle; S F Gilbert; J Grieves; J Anderegg; R Rueckert
Journal:  Virology       Date:  1981-11       Impact factor: 3.616

4.  Antigenic structure of poliovirus.

Authors:  R Dernick
Journal:  Dev Biol Stand       Date:  1981

5.  New rapid methods for DNA sequencing based in exonuclease III digestion followed by repair synthesis.

Authors:  L H Guo; R Wu
Journal:  Nucleic Acids Res       Date:  1982-03-25       Impact factor: 16.971

6.  Identification of the initiation site of poliovirus polyprotein synthesis.

Authors:  A J Dorner; L F Dorner; G R Larsen; E Wimmer; C W Anderson
Journal:  J Virol       Date:  1982-06       Impact factor: 5.103

7.  Expression of poliovirus capsid polypeptide VP1 in Escherichia coli.

Authors:  S van der Werf; M Dréano; P Bruneau; H Kopecka; M Girard
Journal:  Gene       Date:  1983-07       Impact factor: 3.688

8.  Topographical studies on poliovirus capsid proteins by chemical modification and cross-linking with bifunctional reagents.

Authors:  K Wetz; K O Habermehl
Journal:  J Gen Virol       Date:  1979-08       Impact factor: 3.891

9.  Comparison of the amino acid sequence of the major immunogen from three serotypes of foot and mouth disease virus.

Authors:  A J Makoff; C A Paynter; D J Rowlands; J C Boothroyd
Journal:  Nucleic Acids Res       Date:  1982-12-20       Impact factor: 16.971

10.  Antiviral effect on MS-2 coliphage obtained with a synthetic antigen.

Authors:  H Langbeheim; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1976-12       Impact factor: 11.205

View more
  22 in total

1.  Molecular basis for linkage of a continuous and discontinuous neutralization epitope on the structural polypeptide VP2 of poliovirus type 1.

Authors:  K J Wiegers; K Wetz; R Dernick
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

2.  Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.

Authors:  B Blondel; R Crainic; O Fichot; G Dufraisse; A Candrea; D Diamond; M Girard; F Horaud
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

3.  A herpesvirus maturational proteinase, assemblin: identification of its gene, putative active site domain, and cleavage site.

Authors:  A R Welch; A S Woods; L M McNally; R J Cotter; W Gibson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

4.  Genetic insertion and exposure of a reporter epitope in the ferrichrome-iron receptor of Escherichia coli K-12.

Authors:  G S Moeck; B S Bazzaz; M F Gras; T S Ravi; M J Ratcliffe; J W Coulton
Journal:  J Bacteriol       Date:  1994-07       Impact factor: 3.490

5.  Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding.

Authors:  C E Fricks; J M Hogle
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

6.  Regions of poliovirus protein VP1 produced in Escherichia coli induce neutralizing antibodies.

Authors:  M E Hoatlin; O M Kew; M E Renz
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

7.  Vaccination against poliomyelitis: present possibilities and future prospects.

Authors:  J L Melnick
Journal:  Am J Public Health       Date:  1988-03       Impact factor: 9.308

8.  Synthetic peptides from four separate regions of the poliovirus type 1 capsid protein VP1 induce neutralizing antibodies.

Authors:  M Chow; R Yabrov; J Bittle; J Hogle; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

9.  Cross-reactions of immunoglobulin M and G antibodies with enterovirus-specific viral structural proteins.

Authors:  F Reigel; F Burkhardt; U Schilt
Journal:  J Hyg (Lond)       Date:  1985-10

10.  Neutralizing monoclonal antibodies to Theiler's murine encephalomyelitis viruses.

Authors:  S Nitayaphan; M M Toth; R P Roos
Journal:  J Virol       Date:  1985-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.